Cancer Research Technology
Log in Register
Menu

Anti-EMA [E29]

Invented by Dr Jacqueline Cordell from University of Oxford
Invented at University of Oxford

Info

Catalogue Number 151381
Applications IHC WB
Antigen/Gene or Protein Targets Epithelial Membrane Antigen (EMA)
Reactivity Human
Relevance Monoclonal antibody used as a pan-epithelial marker to categorise cancers of epithelial origin and detect metastatic loci.

Background and Research Application
Glycoproteins isolated from human milk fat globule membranes, designated epithelial membrane antigen (EMA), have been detected immunohistochemically in most non-neoplastic epithelia and are potentially a highly effective marker for establishing the epithelial nature of neoplastic cells.
Anti-EMA was created for use in diagnostic immunocytochemistry for identification of tumours of epithelial origins.
EMA is present within membranes of the apical side of secretory epithelia, and is typically overexpressed in colon, breast, ovarian, lung and pancreatic cancers.
Host Mouse
Immunogen Human milk fat globule membrane preparation
Immunogen UniProt ID P15941
Subclass IgG2a
Myeloma Used P3/NS1/1-Ag4.1
Recommended Growing Conditions RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT
Notes Original Antibody Development
BALB/c mice were immunised with 50ug of EMA antigen emulsified with Freund’s complete adjuvant, 4 times at 10-day intervals. One mouse was injected intravenously with 100ug of antigen and sacrificed 3 days later. The spleen was harvested aseptically, a cell suspension prepared and fused with NS1 myeloma cells. Following 8 days culture, supernatants were removed and checked for activity by immuno-peroxidase staining on cryostat sections of a ductal breast carcinoma.

Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
Ultroser G can be used at 1% if the cells are not growing well.

Anti-EMA (E29) reacts with a wide variety of human epithelia and mesothelial cells but is unreactive with other cell types (bar the occasional plasma cell). It can detect neoplastic cells in bone marrow smears where they cannot be identified by routine procedure and reacts with a wide variety of neoplastic epithelia and neoplastic mesothelial cells. Anti-EMA can be used to help distinguish mesothelioma, which can be difficult to differentiate from adenocarcinoma, and has been shown to react strongly with neoplastic plasma cells from a case of multiple myeloma, helping with tumour identification. Anti-EMA can help of detect micro-metastases in breast cancer patients in which the tumour was undetectable in routine histological examination. It is a highly valuable antibody when combined with leukocyte-associated antigens monoclonal antibodies as it allows for the majority of anaplastic tumours to be classified as lymphoma or carcinoma.

Anti-EMA reacts with equal intensity to both cryostat and paraffin embedded tissue sections.

Concentration
1mg/ml as standard
Research Area Cancer, Cell Type or Organelle Marker, Cell Signaling & Signal Transduction

References

There are 19 reference entries for this reagent.

View All References

References: 19 entries

A case of a CD56-expressing ectomesenchymal chondromyxoid tumor of the tongue: potential diagnostic usefulness of commonly available CD56 over CD57

IHC

Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?

Europe PMC ID: 27404454

Woei-A-Jin et al. 2016. Br J Cancer. :. PMID: 27404454.

IHC

Maxillary carcinosarcoma: Identification of a novel MET mutation in both carcinomatous and sarcomatous components through next generation sequencing.

Europe PMC ID: 25782598

Liu et al. 2015. Breast Cancer Res Treat. 151(2):443-51. PMID: 25953688.

IHC

Habougit et al. 2015. Int J Surg Pathol. :. PMID: 26113666.

IHC

Mediastinal Mature Teratoma With Malignant Carcinomatous Transformation (Somatic-Type Malignancy) With Metastatic Course.

Europe PMC ID: 26113666

Kim et al. 2015. PLoS One. 10(3):e0120296. PMID: 25798919.

Invasive micropapillary mucinous carcinoma of the breast is associated with poor prognosis.

Europe PMC ID: 25953688

Ohlmann et al. 2015. Ann Diagn Pathol. :. PMID: 25990776.

Sclerosing epithelioid fibrosarcoma of the kidney: clinicopathologic and molecular study of a rare neoplasm at a novel location.

Europe PMC ID: 25990776

Genome-wide transcript profiling reveals novel breast cancer-associated intronic sense RNAs.

Europe PMC ID: 25798919

Ando et al. 2015. Head Neck. :. PMID: 25782598.

ten Berge et al. 2001. J Clin Pathol. 54(12):933-9. PMID: 11729213.

MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.

Europe PMC ID: 11729213

Heyderman et al. 1985. Br J Cancer. 52(3):355-61. PMID: 3899156.

Cordell et al. 1985. Br J Cancer. 52(3):347-54. PMID: 3899155.

A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2.

Europe PMC ID: 3899156

Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry.

Europe PMC ID: 3899155


Add a reference

References: 19 entries

A case of a CD56-expressing ectomesenchymal chondromyxoid tumor of the tongue: potential diagnostic usefulness of commonly available CD56 over CD57

IHC

Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?

Woei-A-Jin et al. 2016. Br J Cancer. :. PMID: 27404454.

IHC

Maxillary carcinosarcoma: Identification of a novel MET mutation in both carcinomatous and sarcomatous components through next generation sequencing.

Liu et al. 2015. Breast Cancer Res Treat. 151(2):443-51. PMID: 25953688.

IHC

Habougit et al. 2015. Int J Surg Pathol. :. PMID: 26113666.

IHC

Mediastinal Mature Teratoma With Malignant Carcinomatous Transformation (Somatic-Type Malignancy) With Metastatic Course.

Kim et al. 2015. PLoS One. 10(3):e0120296. PMID: 25798919.

Invasive micropapillary mucinous carcinoma of the breast is associated with poor prognosis.

Ohlmann et al. 2015. Ann Diagn Pathol. :. PMID: 25990776.

Sclerosing epithelioid fibrosarcoma of the kidney: clinicopathologic and molecular study of a rare neoplasm at a novel location.

Genome-wide transcript profiling reveals novel breast cancer-associated intronic sense RNAs.

Ando et al. 2015. Head Neck. :. PMID: 25782598.

ten Berge et al. 2001. J Clin Pathol. 54(12):933-9. PMID: 11729213.

MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.

Heyderman et al. 1985. Br J Cancer. 52(3):355-61. PMID: 3899156.

Cordell et al. 1985. Br J Cancer. 52(3):347-54. PMID: 3899155.

A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2.

Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry.


Add a reference